Hyperhidrosis: Diagnostic and Therapeutic Strategies

authors:

avatar Bahareh Abtahi-Naeini , * , avatar Atefe Payande , avatar Mehraein Mehraein , avatar Fereshte Rastegarnasab

Koomesh: Vol.25, issue 4; 420-427
published online: August 01, 2023
article type: Research Article
received: August 02, 2023
accepted: December 01, 2023

how to cite: Abtahi-Naeini B, Payande A, Mehraein M, Rastegarnasab F. Hyperhidrosis: Diagnostic and Therapeutic Strategies. koomesh. 2023;25(4):e152840. 

Abstract

Introduction: Hyperhidrosis is a condition characterized by excessive sweating, which may have a primary or secondary cause. The first step in managing hyperhidrosis is to determine the type of hyperhidrosis as primary or secondary. The therapeutic options depend on the type of hyperhidrosis and are divided into topical, systemic, and procedural modalities. Importantly, the first line in the treatment of secondary hyperhidrosis is to remove the underlying cause. Hyperhidrosis can be treated in different ways, but the best option varies depending on the person's specific condition. To decide on the most suitable treatment, a thorough history and clinical examination are necessary, as well as taking into account the patient's personal and social circumstances. To provide comprehensive and up-to-date information about the diagnosis, etiologies, and treatment methods of hyperhidrosis, this article aims to address the significant prevalence of the condition and its impact on various dimensions of the patient's life.

References

  • 1.

    Cerfolio RJ, De Campos JR, Bryant AS, Connery CP, Miller DL, DeCamp MM, et al. The Society of thoracic surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg 2011; 91: 1642-1648.

  • 2.

    Brackenrich J, Fagg C. Hyperhidrosis. Stat Pearls. Treasure Island (FL): Stat Pearls Publishing Copyright 2023, StatPearls Publishing LLC.; 2023.

  • 3.

    Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. J Cosmet Dermatol 2023; 22: 2268-2272.

  • 4.

    Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, Nowicki RJ. Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities. Postepy Dermatol Alergol 2022; 39: 251-257.

  • 5.

    Wrle B, Rapprich S, Heckmann M. Definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges 2007; 5: 625-628.

  • 6.

    Stashak AB, Brewer JD. Management of hyperhidrosis. Clin Cosmet Investig Dermatol 2014; 7: 285-299.

  • 7.

    Lis-wity A. Nadmierna potliwo pierwotna - aktualne moliwoci terapeutyczne. Dermatol Po Dyplomie 2015; 6: 9-17.

  • 8.

    Abtahi-Naeini B, Naeini FF, Adibi N, Pourazizi M. Quality of life in patients with primary axillary hyperhidrosis before and after treatment with fractionated microneedle radiofrequency. J Res Med Sci 2015; 20: 631-635.

  • 9.

    Dunford LJ, Radley K, McPhee M, McDonald L, Oliver RJ, Alexandroff A, et al. Setting research priorities for management and treatment of hyperhidrosis: the results of the James Lind Alliance Priority Setting Partnership. Clin Exp Dermatol 2022; 47: 1109-1114.

  • 10.

    Maillard H, Lecouflet M. [Management of hyperhidrosis]. Ann Dermatol Venereol 2015; 142: 252-261.

  • 11.

    Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007; 33: 908-923.

  • 12.

    Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up. J Am Acad Dermatol 2019; 81: 657-666.

  • 13.

    Kardyna A. Nadpotliwo - przyczyny i leczenie. Dermatol Kosmetol Prakt 2009; 4: 6-8.

  • 14.

    Solish MJ, Savinova I, Weinberg MJ. A practical approach to the diagnosis and treatment of palmar hyperhidrosis. Plast Reconstr Surg Glob Open 2022; 10: e4172.

  • 15.

    Arora G, Kassir M, Patil A, Sadeghi P, Gold MH, Adatto M, et al. Treatment of Axillary hyperhidrosis. J Cosmet Dermatol 2022; 21: 62-70.

  • 16.

    McConaghy JR, Fosselman D. Hyperhidrosis: Management Options. Am Fam Physician 2018; 97: 729-734.

  • 17.

    Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options. J Am Acad Dermatol 2019; 81: 669-680.

  • 18.

    Glaser DA, Glaser K. Use of systemic therapies to manage focal hyperhidrosis. Mo Med 2015; 112: 287-291.

  • 19.

    Hlzle E. Topical pharmacological treatment. Curr Probl Dermatol 2002; 30: 30-43.

  • 20.

    Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel) 2013; 5: 821-840.

  • 21.

    Stolman LP. Hyperhidrosis: medical and surgical treatment. Eplasty 2008; 8: e22.

  • 22.

    Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management strategies of palmar hyperhidrosis: challenges and solutions. Clin Cosmet Invest Dermatol 2019; 12: 733-744.

  • 23.

    Grabell DA, Hebert AA. Current and emerging medical therapies for primary hyperhidrosis. Dermatol Ther (Heidelb) 2017; 7: 25-36.

  • 24.

    Baumann L, Slezinger A, Halem M, Vujevich J, Mallin K, Charles C, et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005; 31: 263-270.

  • 25.

    Wong NS, Adlam TM, Potts GA, Farshchian M. Hyperhidrosis: a review of recent advances in treatment with topical anticholinergics. Dermatol Ther (Heidelb) 2022; 12: 2705-2714.

  • 26.

    Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 2007; 157: 118-121.

  • 27.

    Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 2008; 158: 1094-1097.

  • 28.

    Kavanagh GM, Burns C, Aldridge RD. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. Br J Dermatol 2006; 155: 487.

  • 29.

    Campanati A, Gregoriou S, Kontochristopoulos G, Offidani A. Oxybutynin for the treatment of primary hyperhidrosis: current state of the art. Skin Appendage Disord 2015; 1: 6-13.

  • 30.

    Asfour L, Moussa A, Littlewood Z, Sharif J, Newsham J, O'Donoghue N, et al. Botulinum toxin A injections in the treatment of axillary hyperhidrosis: a prospective study reviewing quality of life and patient satisfaction in a UK tertiary dermatology centre. Clin Exp Dermatol 2022; 47: 1358-1359.

  • 31.

    Galadari H, Galadari I, Smit R, Prygova I, Redaelli A. Treatment approaches and outcomes associated with the use of abobotulinumtoxinA for the treatment of hyperhidrosis: A systematic review. J Am Acad Dermatol 2021; 85: 1121-1129.

  • 32.

    Nawrocki S, Cha J. Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol 2020; 82: 969-979.

  • 33.

    Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004; 19: S109-115.

  • 34.

    Walling HW, Swick BL. Treatment options for hyperhidrosis. Am J Clin Dermatol 2011; 12: 285-295.

  • 35.

    Campanati A, Gregoriou S, Milia-Argyti A, Kontochristopoulos G, Radi G, Diotallevi F, et al. The pharmacological treatment and management of hyperhidrosis. Expert Opin Pharmacother 2022; 23: 1217-1231.

  • 36.

    Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol 2017; 31: 952-963.

  • 37.

    Patra S, Kaur M, Sharma VK. Stepwise treatment of primary focal hyperhidrosis with aluminum chloride hexahydrate lotion (20%) and oral glycopyrrolate: a retrospective study from a tertiary care center. Dermatol Ther 2020; 33: e13914.

  • 38.

    Thomas L, Fatah S, Carmichael AJ. Tap water iontophoresis may be ineffective for axillary hyperhidrosis. Clin Exp Dermatol 2015; 40: 337-338.

  • 39.

    Bechara FG, Georgas D, Sand M, Stcker M, Othlinghaus N, Altmeyer P, Gambichler T. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg 2012; 38: 736-740.

  • 40.

    Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol 2012; 11: 59-63.

  • 41.

    Cervantes J, Perper M, Eber AE, Fertig RM, Tsatalis JP, Nouri K. Laser treatment of primary axillary hyperhidrosis: a review of the literature. Lasers Med Sci 2018; 33: 675-681.

  • 42.

    Lupin M, Hong HC, OShaughnessy KF. Long-term efficacy and quality of life assessment for treatment of axillary hyperhidrosis with a microwave device. Dermatol Surg 2014; 40: 805-807.

  • 43.

    Hsu TH, Chen YT, Tu YK, Li CN. A systematic review of microwave-based therapy for axillary hyperhidrosis. J Cosmet Laser Ther 2017; 19: 275-282.

  • 44.

    Glaser DA, Coleman WP, 3rd, Fan LK, Kaminer MS, Kilmer SL, Nossa R, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 2012; 38: 185-191.

  • 45.

    Zhang Y, Gong YY, Tang YL, Bai YS, Yang K, Chen HY, et al. Clinical efficacy of microwave in the treatment of axillary osmidrosis and primary hyperhidrosis. Dermatol Ther 2022; 35: e15657.##https://doi.org/10.1111/dth.15657.

  • 46.

    Fatemi Naeini F, Pourazizi M, Abtahi-Naeini B, Nilforoushzadeh MA, Najafian J. A novel option for treatment of primary axillary hyperhidrosis: fractionated microneedle radiofrequency. J Postgrad Med 2015; 61: 141-143.

  • 47.

    Gupta AK, Venkataraman M, Joshi LT, Cooper EA. Potential use of microwave technology in dermatology. J Dermatolog Treat 2022; 33: 2899-2910.

  • 48.

    Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, Nilforoushzadeh MA, Mirmohammadkhani M. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: A sham control study. Australas J Dermatol 2015; 56: 279-284.

  • 49.

    Kim M, Shin JY, Lee J, Kim JY, Oh SH. Efficacy of fractional microneedle radiofrequency device in the treatment of primary axillary hyperhidrosis: a pilot study. Dermatology 2013; 227: 243-249.

  • 50.

    Wen S, Unuma K, Makino Y, Mori H, Uemura K. Fatal consequence after MiraDry treatment: Necrotizing fasciitis complicated with streptococcal toxic shock syndrome. Leg Med (Tokyo) 2022; 58: 102095.

  • 51.

    Wachal K BW, Staniszewski R, Majewska N, Baszak M. Ocena subiektywnej skutecznoci leczenia nadpotliwoci koczyn grnych z zastosowaniem rnych metod. Postep Dermatol Alergol 2009; 26: 501-505.

  • 52.

    Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatol Clin 2014; 32: 533-540.

  • 53.

    Hafner J, Beer GM. Axillary sweat gland excision. Curr Probl Dermatol 2002; 30: 57-63.

  • 54.

    Feldmeyer L, Bogdan I, Moser A, Specker R, Kamarashev J, French LE, Luchli S. Short- and long-term efficacy and mechanism of action of tumescent suction curettage for axillary hyperhidrosis. J Eur Acad Dermatol Venereol 2015; 29: 1933-1937.